Overview
The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.
The main question it aims to answer is:
Can the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?
Researchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.
Participants will:
- use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm).
- receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).
Eligibility
Inclusion Criteria:
- Signed Informed Consent Form (ICF)
- Age ≥ 18 years
- (Self-)admission to the involved Acute Admissions Unit (AAU)
- "Lead symptom" identified as coughing, back pain or abdominal discomfort
- Participant within ESI triage system group 4 (standard) and 5 (non-urgent)
- German-speaking
- Ownership of a smartphone or other mobile device with iOS or Android operating system
Exclusion Criteria:
- Age < 18 years
- Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted
- Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system
- Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial